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Editorials

start of a disease spectrum with cervical
spondylosis as the end product, it is important
to point out that, in Jeffreys' series, 30% of
patients had sufficient extruded disc material
to play an important role in compression of the
cord in addition to that of osteophytic protrusion.
The role of trauma in the development of
CSM is interesting; Jeffreys7 found that 10%
gave a history of a neck injury in the past, 8%
experienced a neck injury which precipitated a
neurological decline and 16% gave a history of
both, i.e. approximately 44% experienced a
neck injury at some time. Nurick found that
14% experienced an injury in the month prior
to admission and which had frequently precipitated the final decline. It would seem that the
past neck injury may have contributed to the
degenerative disease and the precipitating injury in some way further compromised a spinal
cord already in jeopardy.
The role of subluxation in the evolution of
CSM remains problematical. Jeffreys7 found
subluxation to be present in 3% whereas
Nurick4 found that not only did this radiological sign occur in 28.7% but that it tended to be
associated with increasing disability. One possible explanation of this discrepancy may lie in
the fact that in the former series the patients
were more disabled and possibly had more
advanced spondylosis such that their cervical
spines were more rigid and less able to sublux
than those in Nurick's series.
Finally there is the evidence that many
patients improve greatly and rapidly once the
compressive agent has been removed, particularly after anterior cervical decompression and
f ~ s i o n ~ Whereas
.~.
one accepts that decompression successfully carried out could improve cord blood flow and relieve cord stretching the theory most likely to explain a myelopathy is compression of the spinal cord;
provided that one also allows that in any
compression there must be an element of local
ischaemia in the cord at the site of compression, caused by the compressing agent 'squashing' the vascular bed at that point.
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Dexamethasone and the Serious Head
Injury

The serious head injury remains a grave
medical problem with a mortality of about 40%
and a good outcome in only 20% in most large
series round the worldlg. Physical disruption of
neural tissue, ischaemia and oedema are the
pathologic substrates in the diffuse brain
injury2' and therapy aimed at attenuating the
effects of these on intracranial pressure has
been the major preoccupation of those caring
for head injured patients. Thus, after the
demonstration of a dramatic decrease in cerebral oedema associated with brain tumours by
dexamethasone", it was not surprising that the
use of this agent in head injuries rapidly gained
widespread currency. It is now recommended
by most standard textbooks and almost universally used by physicians other than neurosurgeons. Amongst the latter, as so often happens
in medicine, enthusiasm has been tempered by
experience.
Experimental verification of the beneficial
effects of steroids on post-traumatic cerebral
oedema was sought soon after their clinical
introduction. Various animal models and proRICHARD
JEFFREYS tocols were used but conclusions were varied.
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Blinderman et aL3 demonstrated a reduction in
oedema induced by intracarotid injection of
vegetable oil when Solumedrol was infused
during the procedure. Lippert et al. produced
oedema in the brain of the dog by implanting
psyllium seed and began cortisone on the day
of. operation. Their conclusions were equivocal. Long et aZ.I8 on the other hand found
reduction in psyllium induced oedema in the
rabbit pre-treated with dexamethasone.
Clasen et aLs produced oedema in monkeys
by freezing through the intact skull but found
no benefit of treatment with prednisolone,
while Benson et aLz were similarly disappointed when steroids did not significantly
lessen laser produced oedema in rats. The cold
injury model was modified to produce local
cooling of the exposed dura or brain in cats and
a definite decrease in cerebral oedema was
observed by Pappius & McCannz3 and
Maxwell et U Z . ~ O but not by Dick et d 9or
Nelsonzz. Kobrine & Kempe16 used a model of
acceleration-deceleration injury in monkeys
and found traumatic brain swelling to be
significantly less in the treated as compared to
control groups with extension of survival as
well. On the other hand the acute head injury
produced in cats with a humane stunner by
Tarnheim & McLaurinz7 was not affected by
dexamethasone therapy. All these models have
concentrated on cerebral oedema and the
relevance of this to the clinical situation is
unclear, particularly as the results of clinical
trials have not been consistent.
The earliest trials were uncontrolled, such as
that by Sparacio et ~ 1who
. showed
~ ~ a superior
outcome in patients with diffuse brain injury
treated with high dose methylprednisolone
when compared to the author’s previous experience but no benefit to those with focal lesions.
Looking at patients with traumatic decerebration Gutterman et al.I4 concluded that steroids
did not improve the percentage or quality of
survival from traumatic decerebration and
indeed may have had a deleterious effect.
HoytI5 reported on an unblinded study of 16
patients treated with placebo and dexamethasone with little difference in mortality. A larger
number of patients were entered in a similar

401

trial by Alexander’ with an 8-year study of 110
cases of closed head injury equally divided
between placebo and dexamethasone groups.
He found “that the use of steroids in the
acutely injured patient, though probably not
harmful, is of no real help’’.
Faupel et aZ.1° reported the first double blind
study comparing placebo,low dose dexamethasone and high dose dexamethasone in patients
with severe closed head injury. There was a
significant reduction in mortality in the treated
patients (57% in placebo group versus 24% in
the combined steroid groups). However, it
must be noted that in the treated group 25.4%
of the survivors were vegetative compared to
3.6% of the placebo group and 11.9% were
severely disabled compared to 7.1% in the
control group. Thus, benefit of steroid in this
trial is less clear when death or poor outcome is
compared to a good or moderate outcome. A
trial of similar design was reported by Gobiet
et allz and a significant reduction in mortality
was claimed. This trial has been criticised on
statistical grounds and because of incomplete
data7. Indeed, uncritical acceptance of data
such as presented in these two trials had given
dexamethasone an authenticity in head injury
management it ill-deserved. Gudeman et all3
in 1979 noted that over the past 10 years
steroids had come to be used routinely in head
injury “despite a disconcerting lack of its
beneficial influence on outcome or on intracranial pressure in such patients”. Their study
of 20 cases not only failed to show benefit,
there was in addition a high incidence of gastric
haemorrhage and hyperglycaemia.
Over the past 8 years four prospective
double-blind controlled trials of high dose
dexamethasone therapy in head injuries have
been publicised. Cooper et aL7 studied 76
patients and found no difference in outcome
between the treated and placebo group, while
infectious complications were more frequent in
the steroid group. The real importance of their
study was the availability of post-mortem data
for 32 of the 39 patients who died and this data
allowed the authors to conclude that 90% of
the deaths could not be influenced by steroid
therapy being due either to severe brain
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injuries with parenchymal haemorrhage and
tissue disruption, recurrent haematomas or
medical complications. Saul et aLZ5studied 100
comatose patients and there was no significant
difference in outcome between the two groups
though in those treated patients responding
early, a higher incidence of good recovery was
observed. Braakman et aL4 entered 161 patients into their trial and found no difference in
survival or outcome in the whole group or in
any sub-group with varying severity of brain
damage. An increase in pulmonary infection in
the steroid group was observed. Dearden et aL8
reported on 130 severely head injured patients
and found no advantage of high dose dexamethasone on intracranial pressure (ICP) trends
or clinical outcome. Indeed, treated patients
with raised ICP fared worse. They also confirmed the hyperglycaemia shown to be more
frequent in steroid treated patients in previous
trials.
During the last few years attention has
focussed on the metabolic consequences of
severe head injuries and a profound traumatic
response identified by increased energy expenditure, a negative nitrogen balance, hypoalbuminaemia and weight loss has been foundz8.
The metabolic response has been estimated to
be similar to that in patients with burns of
20-40% of body surface6. This catabolic state
is accentuated by steroid administration and in
a study of 20 head injured patients24randomised to methylprednisolone or no steroid, the
patients receiving steroid had a 30% higher
excretion of nitrogen in the first 6 days after
injury. Immunosuppression, evidenced by a
lower total lymphocyte count and a higher
incidence of infections was present in the
treated group; hyperglycaemia requiring insulin was more common in those patientsz4.
Hyperglycaemia has been shown to worsen the
prospects of a recovery of ischaemic neurones
in stroke by increasing local lactic acid concentration and it has been suggested that the same
may happen in head injuries. Raised intracranial pressure causes ischaemia particularly in
the traumatised areas of brain and steroids
may, by inducing hyperglycaemia and its
attendant neuronal lactacidosis, be detrimental

to recovery. If this hypothesis is confirmed,
steroids may be positively contraindicated in
head injuries.
Thus a review of the literature clearly shows
an emerging consensus that dexamethasone
confers no benefit to the seriously head injured
patient and may in fact be harmful. The four
double blind trials quoted above all contained
sufficiently large sample sizes and were methodologically sound enough to make their combined conclusion unassailable. It is unlikely
that any further trial will show a contrary
result.

RASHIDJOOMA
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